Effectiveness of Highly Active Antiretroviral Therapy in HIV-Positive Children: Evaluation at 12 Months in a Routine Program in Cambodia
- 1 November 2007
- journal article
- research article
- Published by American Academy of Pediatrics (AAP)
- Vol. 120 (5), e1134-e1140
- https://doi.org/10.1542/peds.2006-3503
Abstract
OBJECTIVE. Increasing access to highly active antiretroviral therapy to reach all those in need in developing countries (scale up) is slowly expanding to HIV-positive children, but documented experience remains limited. We aimed to describe the clinical, immunologic, and virologic outcomes of pediatric patients with >12 months of highly active antiretroviral therapy in 2 routine programs in Cambodia. METHODS. Between June 2003 and March 2005, 212 children who were younger than 13 years started highly active antiretroviral therapy. Most patients started a standard first-line regimen of lamivudine, stavudine, and nevirapine, using split adult fixed-dosage combinations. CD4 percentage and body weight were monitored routinely. A cross-sectional virologic analysis was conducted in January 2006; genotype resistance testing was performed for patients with a detectable viral load. RESULTS. Mean age of the subjects was 6 years. Median CD4 percentage at baseline was 6. Survival was 92% at 12 months and 91% at 24 months; 13 patients died, and 4 were lost to follow-up. A total of 81% of all patients had an undetectable viral load. Among the patients with a detectable viral load, most mutations were associated with resistance to lamivudine and non–nucleoside reverse-transcriptase inhibitor drugs. Five patients had developed extensive antiretroviral resistance. Being an orphan was found to be a predictor of virologic failure. CONCLUSIONS. This study provides additional evidence of the effectiveness of integrating HIV/AIDS care with highly active antiretroviral therapy for children in a routine setting, with good virologic suppression and immunologic recovery achieved by using split adult fixed-dosage combinations. Viral load monitoring and HIV genotyping are valuable tools for the clinical follow-up of the patients. Orphans should receive careful follow-up and extra support.Keywords
This publication has 14 references indexed in Scilit:
- Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohortAIDS, 2006
- Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapineAIDS, 2005
- Two-Year Clinical and Immune Outcomes in Human Immunodeficiency Virus–Infected Children Who Reconstitute CD4 T Cells Without Control of Viral Replication After Combination Antiretroviral TherapyPublished by American Academy of Pediatrics (AAP) ,2004
- Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'IvoireAIDS, 2004
- Decrease in Hospitalization and Mortality Rates among Children with Perinatally Acquired HIV Type 1 Infection Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2004
- Comprehensive Pediatric Human Immunodeficiency Virus Care and Treatment in Constanta, RomaniaThe Pediatric Infectious Disease Journal, 2004
- PENTA guidelines for the use of antiretroviral therapy, 2004HIV Medicine, 2004
- Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and IrelandBMJ, 2003
- Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected childrenThe Pediatric Infectious Disease Journal, 2003
- Reduction in Mortality With Availability of Antiretroviral Therapy for Children With Perinatal HIV-1 InfectionJAMA, 2000